Bone morphogenic protein type 2 receptor mutation-independent mechanisms of disrupted bone morphogenetic protein signaling in idiopathic pulmonary arterial hypertension

American Journal of Respiratory Cell and Molecular Biology

Volumn 55, Issue 4, 2016, Pages 564-575

  Barnes, Jarrod W ^a   Kucera, Elif T ^a   Tian, Liping ^a   Mellor, Noël E ^a   Dvorina, Nina ^a   Baldwin, William W ^a   Aldred, Micheala A ^a   Farver, Carol F ^a   Comhair, Suzy A A ^a   Aytekin, Metin ^a,b   Dweik, Raed A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

Bone morphogenetic proteins; Gremlin 1; Idiopathic pulmonary arterial hypertension; Smurf 1

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; GLUCOSE; PROTEASOME; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; AIRWAY SMOOTH MUSCLE CELL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE MUTATION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG PARENCHYMA; MALE; MOLECULAR WEIGHT; PLASMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; PULMONARY ARTERY MUSCLE; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; UBIQUITINATION; VASCULAR SMOOTH MUSCLE;

EID: 84992313500     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2015-0402OC     Document Type: Article

References (70)

1. Dweik RA, Rounds S, Erzurum SC, Archer S, Fagan K, Hassoun PM, Hill NS, Humbert M, Kawut SM, Krowka M, et al.; ATS Committee on Pulmonary Hypertension Phenotypes. An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med 2014;189:345-355.
2. Tuder RM, Archer SL, Dorfmü ller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D4-D12.
3. Ghamra ZW, Dweik RA. Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleve Clin J Med 2003;70:S2-S8.
4. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994; 105:37S-41S.
5. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336: 111-117.
6. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-1665.
7. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:13S-24S.
8. Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, Oppedisano R, Thomassen MJ, Erzurum SC. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 158:917-923.
9. Austin ED, Lahm T, West J, Tofovic SP, Johansen AK, Maclean MR, Alzoubi A, Oka M. Gender, sex hormones and pulmonary hypertension. Pulm Circ 2013;3:294-314.
10. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43-S54.
11. Machado RD, Southgate L, Eichstaedt CA, AldredMA, Austin ED, BestDH, Chung WK, Benjamin N, Elliott CG, Eyries M, et al. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. Hum Mutat 2015;36:1113-1127.
12. Anderson L, Lowery JW, Frank DB, Novitskaya T, Jones M, Mortlock DP, Chandler RL, de Caestecker MP. Bmp2 and Bmp4 exert opposing effects in hypoxic pulmonary hypertension. Am J Physiol Regul Integr Comp Physiol 2010;298:R833-R842.
13. Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri FM, Peters DM, Dumitrascu R, Seeger W, Knaus P, et al. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2007;27:1072-1078.
14. Frank DB, Abtahi A, Yamaguchi DJ, Manning S, Shyr Y, Pozzi A, Baldwin HS, Johnson JE, de Caestecker MP. Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res 2005;97:496-504.
15. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005;112:553-562.
16. Long L, Ormiston ML, Yang X, Southwood M, Gra f S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 2015;21:777-785.
17. Austin ED, Loyd JE. Heritable forms of pulmonary arterial hypertension. Semin Respir Crit Care Med 2013;34:568-580.
18. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, West JD, Phillips JA III, Hamid R, Loyd JE. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186:892-896.
19. Yanagita M. BMP antagonists: their roles in development and involvement in pathophysiology. Cytokine Growth Factor Rev 2005; 16:309-317.
20. Rider CC, Mulloy B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem J 2010;429:1-12.
21. Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell 1998;1:673-683.
22. Sun J, Zhuang FF, Mullersman JE, Chen H, Robertson EJ, Warburton D, Liu YH, Shi W. BMP4 activation and secretion are negatively regulated by an intracellular gremlin-BMP4 interaction. J Biol Chem 2006;281:29349-29356.
23. Yue S, Tang LY, Tang Y, Tang Y, Shen QH, Ding J, Chen Y, Zhang Z, Yu TT, Zhang YE, et al. Requirement of Smurf-mediated endocytosis of Patched1 in sonic hedgehog signal reception. eLife 2014;3:3.
24. David D, Nair SA, Pillai MR. Smurf E3 ubiquitin ligases at the cross roads of oncogenesis and tumor suppression. Biochim Biophys Acta 2013;1835:119-128.
25. Khokha MK, Hsu D, Brunet LJ, Dionne MS, Harland RM. Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat Genet 2003;34:303-307.
26. Michos O, Panman L, Vintersten K, Beier K, Zeller R, Zuniga A. Gremlin-mediated BMP antagonism induces the epithelialmesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development 2004;131:3401-3410.
27. Lu MM, Yang H, Zhang L, Shu W, Blair DG, Morrisey EE. The bone morphogenic protein antagonist gremlin regulates proximal-distal patterning of the lung. Dev Dyn 2001;222:667-680.
28. Costello CM, Cahill E, Martin F, Gaine S, McLoughlin P. Role of gremlin in the lung: development and disease. Am J Respir Cell Mol Biol 2010;42:517-523.
29. Zhang Y, Zhang Q. Bone morphogenetic protein-7 and Gremlin: new emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun 2009;383:1-3.
30. Walsh DW, Godson C, Brazil DP, Martin F. Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 2010;20:244-256.
31. Cahill E, Costello CM, Rowan SC, Harkin S, Howell K, Leonard MO, Southwood M, Cummins EP, Fitzpatrick SF, Taylor CT, et al. Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation 2012;125:920-930.
32. Ciuclan L, Sheppard K, Dong L, Sutton D, Duggan N, Hussey M, Simmons J, Morrell NW, Jarai G, Edwards M, et al. Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice. Am J Pathol 2013; 183:1461-1473.
33. Wellbrock J, Harbaum L, Stamm H, Hennigs JK, Schulz B, Klose H, Bokemeyer C, Fiedler W, Lü neburg N. Intrinsic BMP antagonist Gremlin-1 as a novel circulating marker in pulmonary arterial hypertension. Lung 2015;193:567-570.
34. Murakami K, Mathew R, Huang J, Farahani R, Peng H, Olson SC, Etlinger JD. Smurf1 ubiquitin ligase causes downregulation of BMP receptors and is induced in monocrotaline and hypoxia models of pulmonary arterial hypertension. Exp Biol Med (Maywood) 2010;235: 805-813.
35. Marsboom G, Wietholt C, Haney CR, Toth PT, Ryan JJ, Morrow E, Thenappan T, Bache-Wiig P, Piao L, Paul J, et al. Lung 8F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185:670-679.
36. Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, Zhang HJ, Haber I, Rehman J, et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) 2010;88:47-60.
37. Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res 2014;115:148-164.
38. Barnes JW, Tian L, Heresi GA, Farver CF, Asosingh K, Comhair SA, Aulak KS, Dweik RA. O-linked b-N-acetylglucosamine transferase directs cell proliferation in idiopathic pulmonary arterial hypertension. Circulation 2015;131:1260-1268.
39. Barnes J, Dweik RA. Is pulmonary hypertension a metabolic disease? Am J Respir Crit Care Med 2014;190:973-975.
40. Comhair SA, Xu W, Mavrakis L, Aldred MA, Asosingh K, Erzurum SC. Human primary lung endothelial cells in culture. Am J Respir Cell Mol Biol 2012;46:723-730.
41. Asosingh K, Aldred MA, Vasanji A, Drazba J, Sharp J, Farver C, Comhair SA, Xu W, Licina L, Huang L, et al. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol 2008;172:615-627.
42. Aldred MA, Vijayakrishnan J, James V, Soubrier F, Gomez-Sanchez MA, Martensson G, Galie N, Manes A, Corris P, Simonneau G, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006;27:212-213.
43. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008;3:1101-1108.
44. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-675.
45. Zhang L, Zhou F, van Dinther M, Ten Dijke P. Determining TGF-b receptor levels in the cell membrane. Methods Mol Biol 2016;1344:35-47.
46. Zhao K, Shi YB. An anti-cancer Smurf. Cell Biosci 2012;2:10.
47. Cao Y, Zhang L. A Smurf1 tale: function and regulation of an ubiquitin ligase in multiple cellular networks. Cell Mol Life Sci 2013;70: 2305-2317.
48. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999;400:687-693.
49. Marin I. Animal HECT ubiquitin ligases: evolution and functional implications. BMC Evol Biol 2010;10:56.
50. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104:1342-1347.
51. Cao Y, Wang C, Zhang X, Xing G, Lu K, Gu Y, He F, Zhang L. Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation. Sci Rep 2014;4: 4965.
52. Ali IH, Brazil DP. Bone morphogenetic proteins and their antagonists: current and emerging clinical uses. Br J Pharmacol 2014;171: 3620-3632.
53. Brazil DP, Church RH, Surae S, Godson C, Martin F. BMP signalling: agony and antagony in the family. Trends Cell Biol 2015;25: 249-264.
54. Karagiannis GS, Musrap N, Saraon P, Treacy A, Schaeffer DF, Kirsch R, Riddell RH, Diamandis EP. Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression. Biol Chem 2015;396:163-183.
55. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, Gladstone H, Chang HY, Morganroth GS, Oro AE, et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci USA 2006;103: 14842-14847.
56. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 2014;115:176-188.
57. Piao L, Fang YH, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med (Berl) 2013;91: 1185-1197.
58. McMahon R, Murphy M, Clarkson M, Taal M, Mackenzie HS, Godson C, Martin F, Brady HR. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-b1. J Biol Chem 2000;275:9901-9904.
59. Lee JO, Lee SK, Kim N, Kim JH, You GY, Moon JW, Jie S, Kim SJ, Lee YW, Kang HJ, et al. E3 ubiquitin ligase, WWP1, interacts with AMPKa2 and down-regulates its expression in skeletal muscle C2C12 cells. J Biol Chem 2013;288:4673-4680.
60. Li G, Li Y, Liu S, Shi Y, Chi Y, Liu G, Shan T. Gremlin aggravates hyperglycemia-induced podocyte injury by a TGFb/Smad dependent signaling pathway. J Cell Biochem 2013;114:2101-2113.
61. Huang H, Huang H, Li Y, Liu M, Shi Y, Chi Y, Zhang T. Gremlin induces cell proliferation and extra cellular matrix accumulation in mouse mesangial cells exposed to high glucose via the ERK1/2 pathway. BMC Nephrol 2013;14:33.
62. Zhang H, Cui YC, Li K, Yang BQ, Liu XP, Zhang D, Li H, Wu AL, Tang Y. Glutamine protects cardiomyocytes from hypoxia/reoxygenation injury under high glucose conditions through inhibition of the transforming growth factor-b1-Smad3 pathway. Arch Biochem Biophys 2016;596:43-50.
63. Yuan W, Liu W, Cai H, Sun X, Yang D, Xu F, Jin C. SB-431542, a specific inhibitor of the TGF-b type I receptor inhibits hypoxiainduced proliferation of pulmonary artery adventitial fibroblasts. Pharmazie 2016;71:94-100.
64. Wang XB, Wang W, Zhu XC, Ye WJ, Cai H, Wu PL, Huang XY, Wang LX. The potential of asiaticoside for TGF-b1/Smad signaling inhibition in prevention and progression of hypoxia-induced pulmonary hypertension. Life Sci 2015;137:56-64.
65. Zhao L, Yee M, O'Reilly MA. Transdifferentiation of alveolar epithelial type II to type I cells is controlled by opposing TGF-b and BMP signaling. Am J Physiol Lung Cell Mol Physiol 2013;305: L409-L418.
66. Stumm CL, Halcsik E, Landgraf RG, Camara NO, Sogayar MC, Jancar S. Lung remodeling in a mouse model of asthma involves a balance between TGF-b1 and BMP-7. PLoS One 2014;9: e95959.
67. Yu L, Liu X, Cui K, Di Y, Xin L, Sun X, Zhang W, Yang X, Wei M, Yao Z, et al. SND1 acts downstream of TGFb1 and upstream of Smurf1 to promote breast cancer metastasis. Cancer Res 2015;75: 1275-1286.
68. Fu X, Song B, Tian GW, Li JL. The effects of the water-extraction of Astragali Radix and Lycopi herba on the pathway of TGF-Smads-UPP in a rat model of diabetic nephropathy. Pharmacogn Mag 2014;10:491-496.
69. Stabile H, Mitola S, Moroni E, Belleri M, Nicoli S, Coltrini D, Peri F, Pessi A, Orsatti L, Talamo F, et al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood 2007;109: 1834-1840.
70. Maciel TT, Melo RS, Schor N, Campos AH. Gremlin promotes vascular smooth muscle cell proliferation and migration. J Mol Cell Cardiol 2008;44:370-379.